Hamilton S

Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK; Oxford Health Foundation Trust, Warneford Hospital, Oxford OX3 7JX, UK; Department of Psychology, University of Bath, Bath BA2 7AY, UK.

7 papers · 1 preprint

ArticleKetamine

Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learning.

Pulcu E, Costi S, Artiach-Hortelano P +8

Europe PMC2026
PreprintKetamine

Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learning

Pulcu E, Costi S, Artiach-Hortelano P +8

Europe PMC2026
ArticleMDMA

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Mitchell JM, Ot'alora G M, van der Kolk B +16

Europe PMC2024
ArticleMDMA

Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.

Jerome L, Feduccia AA, Wang JB +5

Europe PMC2024
ArticleMDMA

Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Mithoefer MC, Feduccia AA, Jerome L +7

Europe PMC2024
ArticleMDMA

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Mitchell JM, Ot'alora G M, van der Kolk B +16

Europe PMC2023
ArticleMDMA

MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

Mitchell JM, Bogenschutz M, Lilienstein A +35

Europe PMC2023
ArticleMDMA

MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study.

Wolfson PE, Andries J, Feduccia AA +10

Europe PMC2020